Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol

Pain Clinical Trial

Official title:

Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02644187
• Other study ID #: VastraGotaland
• Status: Completed
• Phase: N/A
• First received: December 15, 2015
• Last updated: May 9, 2017
• Start date: December 2015
• Est. completion date: March 2017

Study information

• Verified date: May 2017
• Source: Vastra Gotaland Region
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This pilot study will try to minimize the pain during exposure to a new red light source (RhodoLED®, Biofrontera Bioscience GmbH, Leverkusen, Germany) used for PDT without compromising its effect on AKs.

The study design will have an open and prospective, two-armed, split-face design. Participants with AK lesions distributed symmetrically on the scalp, forehead, cheeks, torso, back, arms and/or dorsal parts of the hands are eligible for inclusion. The purpose is to investigate if a modified irradiation protocol can lower the pain while having the same effect on AK clearance rates as compared to the standard PDT irradiation protocol.

Before any study-related procedures are performed, the participants will be thoroughly informed about the study and will be given the opportunity to ask questions. The participants will thereafter sign and date the informed consent form. This constitutes as visit 0.

On visit 1, a randomization to either the standard or the modified irradiation protocol will be performed on one side of the face/body and the other irradiation protocol will then be applied on the other side of the face/body. The participants should have AKs on two comparable sites, i.e. two cheeks, arms or dorsal parts of the hands. One side will be randomized to receive PDT with BF200-ALA and irradiation with the RhodoLED® lamp and the other side will receive BF200-ALA and the Aktilite CL-128 lamp (PhotoCure ASA, Oslo, Norway), which is the traditional lamp used at our department as mentioned above.

The treatment will be given at visit 1. During the treatment, the participants will be asked continuously, every third minute, to estimate the pain on each treatment side using the visual analogue scale, VAS, (where 0 is no pain and 10 is the worst pain imaginable). At the end of the treatment, the participants will also be asked to summarize the treatment as a whole on the VAS-scale. After visit 1, the participants will fill in a follow-up diary form with questions regarding adverse effects (AEs) during the hours and days after the treatment. The efficacy of the treatment will also be assessed at a follow-up (FU) visit, visit 2. The investigators are aiming for a non-inferior analysis, i.e. the new modified irradiation protocol should be at least as good as the standard irradiation protocol. The randomization is blinded for the investigator at the FU visit to minimize the possibility of favoring one irradiation protocol.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: March 2017
• Est. primary completion date: March 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with symmetrically distributed AKs on the scalp, forehead, cheeks, torso, back, arms and/or dorsal parts of the hands.

• Patients >18 years of age who have signed a written informed consent.

Exclusion Criteria:

• Pregnant or breast-feeding.

• Participating in other clinical study at the same time or within 30 days.

• Conditions associated with poor protocol compliance, e.g. excessive use of alcohol or drug abuse.

Related Conditions & MeSH terms

• Keratosis
• Keratosis, Actinic
• Pain
• Therapy, Photodynamic

Intervention

Device:
• BF-RhodoLED
Infrared light, with total dose of 37J/cm2.
• Aktilite CL128
Infrared light, with total dose of 37J/cm2.

Drug:
• BF200-ALA/5-aminolevulinic acid
Prodrug applied to whole treatment area previous to illumination with either light source.

Locations

Country	Name	City	State
Sweden	Dep. of Dermatology, Sahlgrenska University Hospital	Gothenburg

Sponsors (1)

Lead Sponsor	Collaborator
Vastra Gotaland Region

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain assessment	Pain is assessed on a visual analog scale from 0 to 10 (0=no pain at all, 10=worst pain imaginable). The patient assesses the pain during and after the illumination phase of PDT on both treatment sides.	Directly after PDT
Secondary	Effectiveness of PDT with the RhodoLED lamp	The effectiveness of PDT on both treatment sides will be compared at follow-up after 3 months. The clinical clearance of AK lesions will be measured.	3 months after treatment